Terns Pharmaceuticals Inc (TERN) stock saw a decline, ending the day at $10.02 which represents a decrease of $-0.02 or -0.20% from the prior close of $10.04. The stock opened at $10.25 and touched a ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant ...

Our data suggests that insiders own under 1% of Terns Pharmaceuticals, Inc. in their own names. It appears that the board ...

Terns plans to move to a Phase 2 trial for its TERN-601 small-molecule GLP-1 receptor agonist and will submit the latest data ...

Terns Pharmaceuticals' TERN-601 shows impressive weight loss results in a phase 1 study. Read my thoughts on this weight loss ...

Terns Pharmaceuticals’ weight-loss pill has proved effective in a small trial, but still has much to prove before it can ...

Phase I data for TERN-601 suggests Terns’ oral GLP-1 candidate for obesity could be a contender in the market next to big ...

Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early-stage study, joining ...

Terns Pharmaceuticals shares rose 27% after early trials of their obesity drug showed significant weight loss.

Terns Pharmaceuticals shares surged 34% on positive results for obesity treatment drug TERN-601 in early-stage trial, ...

Anil Chaudhary, a wildlife guide with him, saw 60-70 whiskered terns flying and resting in the area. He guessed there were at ...